Aripiprazole 15 mg Tablets Recalled Due to Manufacturing Practice Deviations
Accord Healthcare is recalling Aripiprazole 15 mg tablets distributed in the United States, Puerto Rico, and Canada due to Current Good Manufacturing Practice (CGMP) deviations found during an FDA inspection.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II classification with no reported illnesses or injuries. The recall was initiated due to Current Good Manufacturing Practice deviations identified during FDA inspection; however, no specific product harm or contamination has been confirmed. This represents a precautionary, quality-based recall without reported adverse health effects, meeting the criteria for Moderate severity.
Plain-English summary
Accord Healthcare, Inc. is recalling Aripiprazole Tablets, USP 15 mg from the U.S. market. The affected product is available in two package sizes: 30-count bottles (NDC 16729-281-10) and 100-count bottles (NDC 16729-281-01). These tablets were manufactured by Intas Pharmaceuticals Limited in India and distributed throughout the United States, Puerto Rico, and Canada. A total of 312,864 bottles are subject to this recall.
The recall was initiated following an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations. CGMP standards ensure that pharmaceutical products are manufactured consistently and meet established quality and purity specifications.
The recall affects multiple batches with expiration dates ranging from August 31, 2023 to July 31, 2025. Patients currently taking this medication and healthcare providers should verify the batch numbers of the product in use to determine if the medication is affected.
Patients with this medication should contact their pharmacy or healthcare provider for guidance. Any adverse events or quality concerns related to this product should be reported to the FDA's MedWatch program.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Psychiatric Medication
- Hazard
- manufacturing-quality
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (17)
- Batches: a) P2004997
- P2004998
- P2004999
- Exp. Date 8/31/2023
- P2101206
- Exp. Date 1/31/2024
- P2102486
- Exp. Date 4/30/2024
- P2106247
- P2105375
- Exp. Date 7/31/2024
- P2107239
- P2107240
- Exp. Date 10/31/2024
- b) P2204222 Exp. Date 7/31/2025
- P2105374 Exp. 7/31/2024
- P2203449 Exp. 5/31/2025
UPCs (2)
- 316729281102
- 316729281010
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole tablets recalled nationwide due to excess active ingredient
FDA (Drugs) · 2025-09-24
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- HighAntipsychotic Drug Recalled for Failed Quality Control Test
FDA (Drugs) · 2023-04-26
- ModeratePrescription drug aripiprazole tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole Tablets Recalled Following FDA Inspection for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27